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ABSTRACT
Disclosed herein are methods for producing a stem cell bank
and providing stem cell samples for purchase or use. Also,
provided herein are embodiments relating to a stem cell bank
and stem cell banking system.
12 Claims, 3 Drawing Sheets
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STEM CELL BANKING SYSTEM

database computer comprising at least one processing module, a display, and a storage medium comprising information
of at least one characteristic for each of said stem cell population; and at least one program code module for causing said
information to be viewable on said display upon command by
a user. In a specific embodiment, the invention pertains to a
stem cell banking system wherein the stem cell populations
comprise stem cells obtained from subjects who have a disease condition. The disease condition may include, but is not
limited to, cardiovascular disease, cancer, neurological disease, such as Alzheimer's disease, Parkinson's disease, Huntington's Chorea, Lou-Gherig's disease, etc. Stem cells are
harvested from different subjects having a different disease,
and the stem cells are characterized. The characteristic(s)
is/are inputted into the database computer. In addition, or
alternatively, cells are characterized based on a specific phenotype not necessarily associated with a disease condition.
For example, not to be construed as limiting, liver cells can be
characterized based on their ability to metabolized certain
compounds such as caffeine, alcohol, drug agents, etc. to
study genetic bases of such different metabolism abilities, or
underlying physiology associated therewith. Other types of
cells can be characterized based on functional and/or morphological phenotypes.
Examples, include, but are not limited to, mesenchymal
stem cells (MeSCs ), neural stem cells (NSCs ), hematopoietic
stem cells (HSCs ), fibroblasts or endothelial cells. Population
of stem cells can be derived from a number of different
sources. Stem populations useful in conjunction with certain
embodiments described herein include, but are not limited to,
brain-derived neural stem cells, bone marrow derived mesenchymal stem cells, adipose-derived mesenchymal stem cells,
blood-derived hematopoietic stem cells, cord-blood-derived
stem cells.
In certain embodiments, the harvested cells may be subjected to conditions to influence differentiation or dedifferentiation through introduction of engineered vectors, or other
genetic material. Dedifferentiation comprises the manipulation of a cell such that it takes on the properties of a less
differentiated cell. U.S. application Ser. Nos. 11/258,401;
11/258,603; 11/258,392 and 11/258,360 discuss various
methods for biasing potency and/or differentiation of stem
cells, and are incorporated herein by reference.
In a specific example, adult somatic cells including but not
limited to white blood cells, fibroblasts, mesenchymal stem
cells, and skin cells can be treated with nucleotide derivatives
such as BrdU or 5-azacytidine to epigenetically modify the
cells to increase their developmental potential. Additionally,
cells can be treated with genes that expand the potency of cells
including but not limited to genes that are responsible for
maintaining the properties of embryonic stem cells such as
nanog.
Cells can be positively selected for using cell-specific
markers including but not limited to CD34, CD133 (hematopoietic stem cells), STR0-1, SH2, SH3, (mesenchymal stem
cells), nestin, PSA-NCAM (neural stem cells). Cells can also
be purified through negative selection by selecting out cells
that express markers not present in the desired cell population. For example, lineage markers indicating differentiation
such as CD38, CD45, and "Lin" markers (blood cell lineage
proteins expressed in differentiating blood cells) can select
out white blood cells from a mixture of cells.
Cells can also be selected using physical properties such as
growth characteristics, adhesion, and/or density. For
example, a density gradient can separate red blood cells from

BACKGROUND
Much research is being conducted to study stem cells and
to devise ways of utilizing stem cells in treating various
neurological diseases and injuries, as well as diseases and
injuries of other organ systems. It is generally recognized that
stem cell technologies hold tremendous promise for treating
and ultimately curing neurologically related diseases, injuries
or dysfunctions and those of other organ systems. However,
despite the interest in stem cell research, scientists do not have
a systematic system for obtaining stem cells for research
purposes.
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows a diagram of a stem cell banking system
embodiment.
FIG. 2 shows a flow diagram of a method embodiment for
producing a stem cell bank.
FIG. 3 shows a flow diagram of a method embodiment for
providing for purchase of stem cell samples.
DETAILED DESCRIPTION
The subject invention is based on the inventors' realization
that there is a need for a convenient systematic access to
different stem cell lines. The inventors have realized that the
ability to identify stem cell lines derived from somatic cells
harvested from healthy subjects and subjects having known
disease states or disease symptoms would be invaluable to
researchers. Subjects may be human or nonhuman vertebrates. The inventors have developed methods of harvesting
somatic cells, processing cells to increase their potency and
cataloguing cells according to specific characteristics and
traits.
For example, according to another embodiment, cells are
harvested, catalogued according to predetermined characteristics, e.g., phenotypic information, morphological characteristics, differentiation profile, blood type, major histocompatibility complex, disease state of donor, or genotypic
information (e.g. single nucleated polymorphisms, 'SNPs' of
a specific nucleic acid sequence associated with a gene, or
genomic or mitochondrial DNA), and stored under appropriate conditions (typically by freezing) to keep the stem cells
alive and functioning. Cataloguing may constitute creating a
centralized record of the characteristics obtained for each cell
population, such as, but not limited to, an assembled written
record or a computer database with information inputted
therein. Essentially, this embodiment pertains to the production of a stem cell bank. The stem cell bank facilitates the
selection from a plurality of samples of a specific stem cell
sample suitable for a researcher's needs. Thus, another
embodiment of the subject invention pertains to a stem cell
bank comprising a plurality of stem cells samples obtained
from separate sources and which are characterized and catalogued according to at least one predetermined characteristic.
An additional embodiment pertains to a method of establishing a stem cell bank comprising collecting stem samples from
multiple sources; cataloguing the samples according to at
least one predetermined characteristic and storing the cells
under conditions that keep cells viable.
According to a specific embodiment, the subject invention
pertains to a stem cell banking system comprising a plurality
of stem cell populations disposed in individual containers
under conditions to keep said stem cell populations viable; a
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a solution of bone marrow and adhesion of cells to a culture
flask can select for mesenchymal cells (while hematopoietic
cells remain non-adherent).
As discussed above, stem cells may be procured using
convention techniques in the stem cell art. In one example,
stem cells are obtained from bone marrow or blood. See, for
example, Friedenstein A J, Gorskaja J F, Kulagina N N, Exp
Hematol. 1976 September; 4(5):267-74; and Caplan A I J,
Orthop Res. 1991 September; 9(5):641-50. A bone marrow
sample is explanted from a donor and hematopoietic stem
cells are isolated from the marrow sample according to
known techniques, including use flow cytometry or an affinity
column. See, for example, U.S. Patent Publication Nos.
20040265996;
20050158857;
20060088890;
and
20060073124. In a specific embodiment, hematopoietic cells
are isolated using positive or negative selection. See U.S.
Patent Publication No. 20060073124. Negative selection
removes unwanted cells using certain markers such as C45 or
positive selection using CD34.
Once cells are isolated they may be cultured, expanded,
subjected to external biasing factors and/or genetically modified by introduction of genes encoding for biasing factors, see
U.S. application Ser. Nos 11/258,401; 11/258,603; 11/258,
392 and 11/258,360 are incorporated herein by reference.
Mesenchymal cells may be isolated by similar techniques or
through the use of a gradient, such as FI COL gradient. Mesenchymal cells in a bone marrow sample will attach to surface, whereas other undesired cells will not attach and remain
in the media. The media with the undesired cells is removed
leaving the desired mesenchymal cells. The mesenchymal
cells, as with other cells, are cultured, expanded, subjected to
external biasing factors and/or genetically modified.
In the context of the present application, a polynucleotide
sequence is "homologous" with the sequence according to the
invention if at least 70%, preferably at least 80%, most preferably at least 90% of its base composition and base sequence
corresponds to the sequence according to the invention.
According to the invention, a "homologous protein" is to be
understood to comprise proteins which contain an amino acid
sequence at least 70% of which, preferably at least 80% of
which, most preferably at least 90% of which, corresponds to
a given amino acid sequence; wherein corresponds is to be
understood to mean that the corresponding amino acids are
either identical or are mutually homologous amino acids. The
expression "homologous amino acids" denotes those which
have corresponding properties, particularly with regard to
their charge, hydrophobic character, steric properties, etc.
Thus, in one embodiment the protein may be from 70% up to
less than 100% homologous to nanog (SEQ ID NO. 2).
Homology, sequence similarity or sequence identity of
nucleotide or amino acid sequences may be determined conventionally by using known software or computer programs
such as the BestFit or Gap pairwise comparison programs
(GCG Wisconsin Package, Genetics Computer Group, 575
Science Drive, Madison, Wis. 53711). BestFit uses the local
homology algorithm of Smith and Waterman, Advances in
Applied Mathematics 2: 482-489 (1981), to find the best
segment of identity or similarity between two sequences. Gap
performs global alignments: all of one sequence with all of
another similar sequence using the method of Needleman and
Wunsch, J. Mo!. Biol. 48:443-453 (1970). When using a
sequence alignment program such as BestFit, to determine
the degree of sequence homology, similarity or identity, the
default setting may be used, or an appropriate scoring matrix
may be selected to optimize identity, similarity or homology
scores. Similarly, when using a program such as BestFit to
determine sequence identity, similarity or homology between

two different amino acid sequences, the default settings may
be used, or an appropriate scoring matrix, such as blosum45
or blosum80, may be selected to optimize identity, similarity
or homology scores.
The term "isolated" means separated from its natural environment.
The term "polynucleotide" refers in general to polyribonucleotides and polydeoxyribonucleotides, and can denote an
unmodified RNA or DNA or a modified RNA or DNA.
The term "polypeptides" is to be understood to mean peptides or proteins which contain two or more amino acids
which are bound via peptide bonds.
The polypeptides for use in accord with the teachings
herein include polypeptides corresponding to nanog, and also
includes those, at least 70% of which, preferably at least 80%
of which, are homologous with the polypeptide corresponding to nanog, and most preferably those which exhibit a
homology of least 90% to 95% with the polypeptide corresponding to nanog and which have dedifferentiating influence. Thus, the polypeptides may have a homology of from
70% to up to 100% with respect to SEQ ID NO. 2.
As used herein, a "polypeptide sequence exhibiting dedifferentiating influence" is a polypeptide whose presence in the
cell causes an increase in potency, or transformation from a
less developmentally potent cell to a more developmentally
potent cell. Examples of such polypeptide sequences include
the expression products of SEQ ID NO. 1, and polynucleotide
sequences that hybridize to the complement of SEQ ID NO. 1,
as well as expression products of the polynucleotide
sequences listed in Table 1:
Table 1
Pem (mouse GI: 1255173)
Fan Y, et al. Developmental Biology 210: 481-496. 1999
POU5Fl (Unigene Hs.2860)
Sox2 (Unigene Hs.816)
HESXl (Unigene Hs.171980)
UTFl (Unigene Hs.158307)
REX! (Unigene Hs.335787)
FOXD3 (Unigene Hs.120204)
GBX2 (Unigene Hs.326290)
NANOG (Unigene Hs.326290)
LIN-28 (Unigene 86154)
TGIF
DNMT3A/B (251673)
TGFFl (75561)
Richards M, et al. Stem Cells 22: 51-64. 2004
EGS-1 (accession# X57708.1)
FGF4 Tanaka T, et al. Genone Research 12: 1921-1928.
2002.
Rex-1 (accession# AF 4 5 0 4 5 4)
The terms "stringent conditions" or "stringent hybridization conditions" includes reference to conditions under which
a polynucleotide will hybridize to its target sequence, to a
detectably greater degree than other sequences (e.g., at least
2-fold over background). Stringent conditions are sequencedependent and will be different in different circumstances. By
controlling the stringency of the hybridization and/or washing conditions, target sequences can be identified which are
100% complementary to the probe (homologous probing).
Alternatively, stringency conditions can be adjusted to allow
some mismatching in sequences so that lower degrees of
similarity are detected (heterologous probing).
Typically, stringent conditions will be those in which the
salt concentration is less than about 1.5 M Na ion, typically
about 0.01 to 1.0 MNa ion concentration (orother salts) at pH
7 .0 to 8.3 and the temperature is at least about 30° C. for short
probes (e.g., !Oto 50 nucleotides) andat least about 60° C. for
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long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. Exemplary low stringency
conditions include hybridization with a buffer solution of30
to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl
sulphate) at 37° C., anda wash in lx to 2xSSC (20xSSC=3.0
M NaCl/0.3 M trisodium citrate) at 50 to 55° C. Exemplary
moderate stringency conditions include hybridization in 40 to
45%formamide, 1MNaCl,1%SDSat37°C.,andawashin
0.5x to lxSSC at 55 to 60° C. Exemplary high stringency
conditions include hybridization in 50% formamide, 1 M
NaCl, 1% SDS at 37° C., and a washinO.lxSSC at 60 to 65°
C.
Specificity is typically the function of post-hybridization
washes, the critical factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids,
the Tm can be approximated from the equation of Meinkoth
and Wahl, Anal. Biochem., 138:267-284 (1984): Tm=81.5°
C.+16.6 (log M)+0.41 (% GC)-0.61 (% form)-500/L; where
M is the molarity of monovalent cations, % GC is the percentage of guano sine and cytosine nucleotides in the DNA, %
form is the percentage of formamide in the hybridization
solution, and Lis the length of the hybrid in base pairs. The
Tm is the temperature (under defined ionic strength and pH)
at which 50% of a complementary target sequence hybridizes
to a perfectly matched probe. Tm is reduced by about 1° C. for
each 1% of mismatching; thus, Tm, hybridization and/or
wash conditions can be adjusted to hybridize to sequences of
the desired identity. For example, if sequences with approximately 90% identity are sought, the Tm can be decreased 10°
C. Generally, stringent conditions are selected to be about 5°
C. lower than the thermal melting point (Tm) for the specific
sequence and its complement at a defined ionic strength and
pH. However, severely stringent conditions can utilize a
hybridization and/or wash at 1, 2, 3, or 4 ° C. lower than the
thermal melting point (Tm); moderately stringent conditions
can utilize a hybridization and/or wash at 6, 7, 8, 9, or 10° C.
lower than the thermal melting point (Tm); low stringency
conditions can utilize a hybridization and/or wash at 11, 12,
13, 14, 15, or 20° C. lower than the thermal melting point
(Tm). Using the equation, hybridization and wash compositions, and desired Tm, those of ordinary skill will understand
that variations in the stringency of hybridization and/or wash
solutions are inherently described. If the desired degree of
mismatching results in a Tm of less than 45° C. (aqueous
solution) or 32° C. (formamide solution) it is preferred to
increase the SSC concentration so that a higher temperature
can be used. An extensive guide to the hybridization of
nucleic acids is found in Current Protocols in Molecular
Biology, Chapter 2, Ausubel, et al., Eds., Greene Publishing
and Wiley-Interscience, New York (2000).
Accordingly, polynucleotide sequences that hybridize to
the complement of the sequence in SEQ ID NO. 1 are contemplated for use in dedifferentiating cells as taught herein.
According to another embodiment, the subject invention
comprises a method of influencing transcription of an endogenous polynucleotide sequence comprising contacting a nonembryonic cell or cellular component comprising an endogenous polynucleotide sequence with a nanog protein or
protein encoded by a polynucleotide sequence that hybridizes
to a complement of SEQ ID NO. 1 under stringent conditions
(i.e. nanog-like protein). Such influence may further include,
but is not limited to, demethylation of DNA and reversal
histone acetylation. The nanog protein or nanog-like protein
may be one expressed by a polynucleotide sequence introduced in the cell or cellular component, or protein delivered
into the cell or cellular component, or protein expressed by an

endogenous polynucleotide sequence that has been activated.
Nanog expression may be activated by the provision of Oct 4
and/or Sox2, which typically form a dimer. In a specific
embodiment, the cellular component is a nucleus, liposome,
or mitochondria. Such endogenous polynucleotide sequence
or cellular component contacted by nanog or nanog may be
removed from a cell or cellular component and introduced
into another cell or cellular component.
10
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Stem Cell Bank System Embodiment
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In one embodiment, as shown in FIG. 1, the subject invention relates to a stem cell banking system embodiment 100
comprising a stem cell bank 105. A plurality of stem cell
populations are processed, such as by the method discussed in
FIG. 2. In a specific embodiment, the stem cell populations
102 are stored in a housing facility 101 comprising the suitable freezing systems to maintain stem cells in a viable condition. Freezing systems may include but are not limited to a
conventional freezer or a chamber holding a freezing medium
such as liquid nitrogen, dry ice, frozen water, etc. The stem
cell bank 105 maintains a stem cell database computer unit
107. Users 112, 114, 116 each having user computer units
113, 115, 117 that interface with database computer unit 107
via a network connection 109. Each computer unit comprises
at least one processing module 120, 121, 122, and 123,
respectively, for processing information. Furthermore, each
computer unit is communicatingly connected to a display
130, 131, 132, and 133. Information directed to stem cell
populations 102 are stored on database computer 107 which
are conveyed to users 112, 114, 116 on user computer units
113, 115, and 117 via network connection, such as according
to FIG. 3 as described in further detail below. The system
provides the customer the ability to evaluate stem cell populations to determine which are suitable for their ongoing
research and facilitates the transaction of purchasing stem
cells and proper shipment.
As will be appreciated by one of skill in the art, embodiments of the present invention may be embodied as a device
or system comprising a processing module, and/or computer
program product comprising at least one program code module. Accordingly, the present invention may take the form of
an entirely hardware embodiment or an embodiment combining software and hardware aspects. Furthermore, the present
invention may include a computer program product on a
computer-usable storage medium having computer-usable
program code means embodied in the medium. Any suitable
computer readable medium may be utilized including hard
disks, CD-ROMs, DVDs, optical storage devices, or magnetic storage devices.
The term "processing module" may include a single processing device or a plurality of processing devices. Such a
processing device may be a microprocessor, micro-controller, digital signal processor, microcomputer, central processing unit, field programmable gate array, progranimable logic
device, state machine, logic circuitry, analog circuitry, digital
circuitry, and/or any device that manipulates signals (analog
and/or digital) based on operational instructions. The processing module may have operationally coupled thereto, or
integrated therewith, a memory device. The memory device
may be a single memory device or a plurality of memory
devices. Such a memory device may be a read-only memory,
random access memory, volatile memory, non-volatile
memory, static memory, dynamic memory, flash memory,
and/or any device that stores digital information. A computer,

US 8,759,090 B2
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as used herein, is a device that comprises at least one processing module, and optionally at least one memory device.
The computer-usable or computer-readable medium may
be or include, for example, but not limited to, an electronic,
magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, device, or propagation medium. More
specific examples (a non-exhaustive list) of the computerreadable medium would include the following: an electrical
connection having one or more wires, a portable computer
diskette, a random access memory (RAM), a read-only
memory (ROM), an erasable progranmiable read-only
memory (EPROM or Flash memory), an optical fiber, and a
portable compact disc read-only memory (CD-ROM), a CD
ROM, a DVD (digital video disk), or other electronic storage
medium. Note that the computer-usable or computer-readable medium could even be paper or another suitable medium
upon which the program is printed, as the program can be
electronically captured, via, for instance, optical scarming of
the paper or other medium, then compiled, interpreted or
otherwise processed in a suitable marmer if necessary, and
then stored in a computer memory.
Computer program code for carrying out operations of
certain embodiments of the present invention may be written
in an object oriented and/or conventional procedural programming languages including, but not limited to, Java,
Smalltalk, Perl, Python, Ruby, Lisp, PHP, "C", FORTRAN,
or C++. The program code may execute entirely on the user's
computer, partly on the user's computer, as a stand-alone
software package, partly on the user's computer and partly on
a remote computer or entirely on the remote computer. In the
latter scenario, the remote computer may be connected to the
user's computer through a local area network (LAN) or a
wide area network (WAN), or the connection may be made to
an external computer (for example, through the Internet using
an Internet Service Provider).
Certain embodiments of the present invention are
described herein with reference to flowchart illustrations and/
or block diagrams of methods, apparatus (systems) and computer program products according to embodiments of the
invention. It will be understood that each block of the flowchart illustrations and/or block diagrams, and combinations
of blocks in the flowchart illustrations and/or block diagrams,
can be implemented by computer-readable program code
modules. These program code modules may be provided to a
processing module of a general purpose computer, special
purpose computer, embedded processor or other programmable data processing apparatus to produce a machine, such
that the program code modules, which execute via the processing module of the computer or other programmable data
processing apparatus, create means for implementing the
functions specified in the flowchart and/or block diagram
block or blocks.
These computer program code modules may also be stored
in a computer-readable memory that can direct a computer or
other programmable data processing apparatus to function in
a particular manner, such that the program code modules
stored in the computer-readable memory produce an article of
manufacture.
The computer program code modules may also be loaded
onto a computer or other programmable data processing
apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to
produce a computer implemented process such that the
instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart and/or block diagram block or
blocks.

Example 2
Harvesting and Processing of Stem Cells
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FIG. 2 illustrates one embodiment 200 of a method for
harvesting and processing of stem cells for production of a
stem cell bank. A plurality of cell donors are identified 205. In
certain embodiments, donors are chosen due to the presence
of a certain genetic profile and/or disease condition. Cells are
harvested from individual donors 210. Numerous cell types
may be suitable for harvesting including, including, but not
limited to the cells types described above. Harvested stem
cells are dedifferentiated 215. This may be achieved by a
number of different methods as discussed above. Dedifferentiated stem cells are expanded 225 and then stored under
conditions to keep them viable 230. Cells at any of steps 210,
215, 225, or 230 are studied to obtain information concerning
predetermined characteristics, and such information is
optionally inputted into a database computer unit, such as that
described in FIG. 1.
FIG. 3 describes a method embodiment 300 for providing
information about cells at a stem cell bank, such information
being previously inputted into a database computer unit and
made available to users on a network, and to provide for
purchase of stem cells. A request is received from a user to
obtain information about stem cells 305, such as a request to
determine availability of a stem cell sample correlating to
certain keywords, and information is displayed to user regarding one or more stem cells 310, such as stem cells most
closely matching keyword criteria. Providing an indication
that no stem cells match the keyword criteria is also contemplated in an alternate embodiment. Furthermore, optionally,
upon listing one or more stem cells most closely matching
keyword criteria, a request for more detailed information
about specific selected stem cell population(s) is received 315
and more detailed information concerning such selected
population(s) is displayed to user. A request from User to
purchase selected stem cells is received 330 and a confirmation of purchase is sent to the user 335. Purchased stem cells
may then be shipped to customer and the shipping address
provided by user 340.
Example 3
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Methods of Using Identified Stem Cell Populations
As discussed above, the stem cells of the stem cell bank
have increased potency which allows for their implementation in the same types of toxicology studies that are conducted
with embryonic stem cells. See, for example, U.S. Patent
Publication Nos. 20020045179 and 20020012905; as well as
Toxicological Sciences 79, 214-223 (2004) which is itselfand
the references its cites incorporated herein by way of support
for various toxicology studies for which the stem cell banking
system can be used. The following references cited in the
2004 paper are particularly helpful:
Genschow, E., Scholz, G., Brown, N., Piersma, A., Brady, M.,
Clemann, N., Huuskonen, H., Paillard, F., Bremer, S.,
Becker, K., and Spielmann, H. (2000). Development of
prediction models for three in vitro embryotoxicity tests in
an ECVAM validation study. In Vitro Mal. Tax. 13, 51-65.
Rohwedel, J., Guan, K., Hegert, C., and Wobus,A. M. (2001).
Embryonic stem cells as an in vitro model for mutagenicity, cytotoxicity and embryotoxicity studies: present state
and future prospects. Tax. in Vitro 15, 741-753
Kehat, I., Kenyagin-Karsenti, D., Snir, M., Segev, H., Amit,
M., Gepstein, A. S., Livne, E., Binah, 0., Itskovitz-Eldor,
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J., and Gepstein, L. (2001). Human embryonic stem cells
While various embodiments of the present invention have
can differentiate into myocytes with structural and funcbeen shown and described herein, it will be obvious that such
embodiments are provided by way of example only. Numertional properties of cardiomyocytes. J. Clin. Invest. 108,
407-414.
ous variations, changes and substitutions may be made withScholz, G., Genschow, E., Pohl, I., Bremer, S., Paparella, M.,
out departing from the invention herein. Accordingly, it is
and Raabe, H. (1999). Prevalidation of the embryonic stem
intended that the invention be limited only by the spirit and
cell test EST-A new in vitro embryotoxicity test. Toxicol
scope of the appended claims.
In Vitro 13, 675-681.
U.S. Pat. Nos. 5,993,387; 6,493,724 and 6,640,211 are
cited to for background information about sample banking
Kehat, I., Gepstein, A., Spira, A., Iskovitz-Eldor, J., and Gepstein, L. (2002). High-resolution electrophysiological 10 systems. The teachings of all references cited herein are
assessment of human embryonic stem cell-derived cardiincorporated by reference in their entirety to the extent not
omyocytes. Circ. Res. 91, 659-661.
inconsistent with the teachings herein.
SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 2
<210>
<211>
<212>
<213>
<220>
<221>
<222>

SEQ ID NO 1
LENGTH, 1628
TYPE, DNA
ORGANISM, Homo sapiens
FEATURE,
NAME/KEY, CDS
LOCATION, (28) .. (945)

<400> SEQUENCE, 1
tttttcctcc tcttcctcta tactaac atg agt gtg gat cca get tgt ccc caa

54

Met Ser Val Asp Pro Ala Cys Pro Gln
1

5

age ttg cct tgc ttt gaa gaa tee gac tgt aaa gaa tct tea cct atg
Ser Leu Pro Cys Phe Glu Glu Ser Asp Cys Lys Glu Ser Ser Pro Met
10
15
20
25

102

cct gtg att tgt ggg cct gaa gaa aac tat cca tee ttg caa atg tct
Pro Val Ile Cys Gly Pro Glu Glu Asn Tyr Pro Ser Leu Gln Met Ser
30
35
40

150

tct get gag atg cct cac aca gag act gtc tct cct ctt cct tee tee

198

Ser Ala Glu Met Pro His Thr Glu Thr Val Ser Pro Leu Pro Ser Ser
45
50
55
atg gat ctg ctt att cag gac age cct gat tct tee ace agt ccc aaa

246

Met Asp Leu Leu Ile Gln Asp Ser Pro Asp Ser Ser Thr Ser Pro Lys
60
65
70
ggc aaa caa ccc act tct gca gag aat agt gtc gca aaa aag gaa gac

294

Gly Lys Gln Pro Thr Ser Ala Glu Asn Ser Val Ala Lys Lys Glu Asp
75
80
85
aag gtc ccg gtc aag aaa cag aag ace aga act gtg ttc tct tee ace

342

Lys Val Pro Val Lys Lys Gln Lys Thr Arg Thr Val Phe Ser Ser Thr
90
95
100
105
cag ctg tgt gta etc aat gat aga ttt cag aga cag aaa tac etc age
Gln Leu Cys Val Leu Asn Asp Arg Phe Gln Arg Gln Lys Tyr Leu Ser
110
115
120

390

etc cag cag atg caa gaa etc tee aac ate ctg aac etc age tac aaa

438

Leu Gln Gln Met Gln Glu Leu Ser Asn Ile Leu Asn Leu Ser Tyr Lys
125
130
135
cag gtg aag ace tgg ttc cag aac cag aga atg aaa tct aag agg tgg
Gln Val Lys Thr Trp Phe Gln Asn Gln Arg Met Lys Ser Lys Arg Trp
140
145
150

486

cag aaa aac aac tgg ccg aag aat age aat ggt gtg acg cag aag gee
Gln Lys Asn Asn Trp Pro Lys Asn Ser Asn Gly Val Thr Gln Lys Ala
155
160
165

534

tea gca cct ace tac ccc age etc tac tct tee tac cac cag gga tgc

582

Ser Ala Pro Thr Tyr Pro Ser Leu Tyr Ser Ser Tyr His Gln Gly Cys
170
175
180
185
ctg gtg aac ccg act ggg aac ctt cca atg tgg age aac cag ace tgg
Leu Val Asn Pro Thr Gly Asn Leu Pro Met Trp Ser Asn Gln Thr Trp

630
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-continued
190

195

200

aac aat tea ace tgg age aac cag ace cag aac ate cag tee tgg age
Asn Asn Ser Thr Trp Ser Asn Gln Thr Gln Asn Ile Gln Ser Trp Ser
205
210
215

678

aac cac tee tgg aac act cag ace tgg tgc ace caa tee tgg aac aat
Asn His Ser Trp Asn Thr Gln Thr Trp Cys Thr Gln Ser Trp Asn Asn
220
225
230

726

cag gee tgg aac agt ccc ttc tat aac tgt gga gag gaa tct ctg cag
Gln Ala Trp Asn Ser Pro Phe Tyr Asn Cys Gly Glu Glu Ser Leu Gln
235
240
245

774

tee tgc atg cac ttc cag cca aat tct cct gee agt gac ttg gag get
Ser Cys Met His Phe Gln Pro Asn Ser Pro Ala Ser Asp Leu Glu Ala
250
255
260
265

822

gee ttg gaa get get ggg gaa ggc ctt aat gta ata cag cag ace act
Ala Leu Glu Ala Ala Gly Glu Gly Leu Asn Val Ile Gln Gln Thr Thr
270
275
280

870

agg tat t t t agt act cca caa ace atg gat tta ttc eta aac tac tee
Arg Tyr Phe Ser Thr Pro Gln Thr Met Asp Leu Phe Leu Asn Tyr Ser
285
290
295

918

atg aac atg caa cct gaa gac gtg tga agatgagtga aactgatatt
Met Asn Met Gln Pro Glu Asp Val
300
305

965

actcaatttc agtctggaca ctggctgaat ccttcctctc ccctcctccc atccctcata

1025

ggatttttct tgtttggaaa ccacgtgttc tggtttccat gatgcctatc cagtcaatct

1085

catggagggt ggagtatggt tggagcctaa tcagcgaggt ttcttttttt ttttttccta

1145

ttggatcttc ctggagaaaa tacttttttt tttttttttg agacggagtc ttgctctgtc

1205

gcccaggctg gagtgcagtg gcgcggtctt ggctcactgc aagctccgcc tcccgggttc

1265

acgccattct cctgcctcag cctcccgagc agctgggact acaggcgccc gccacctcgc

1325

ccggctaata ttttgtattt ttagtagaga cagggtttca ctgtgttagc caggatggtc

1385

tcgatctcct gaccttgtga tccgcccgcc tcggcctccc taacagctgg gattacaggc

1445

gtgagccacc gcgccctgcc tagaaaagac attttaataa ccttggctgc taaggacaac

1505

attgatagaa gccgtctctg gctatagata agtagatcta atactagttt ggatatcttt

1565

agggtttaga atctaacctc aagaataaga aatacaagta cgaattggtg atgaagatgt

1625

att

1628

<210>
<211>
<212>
<213>

SEQ ID NO 2
LENGTH, 305
TYPE, PRT
ORGANISM, Homo sapiens

<400> SEQUENCE, 2
Met Ser Val Asp Pro Ala Cys Pro Gln Ser Leu Pro Cys Phe Glu Glu
1
5
10
15
Ser Asp Cys Lys Glu Ser Ser Pro Met Pro Val Ile Cys Gly Pro Glu
20
25
30
Glu Asn Tyr Pro Ser Leu Gln Met Ser Ser Ala Glu Met Pro His Thr
35
40
45
Glu Thr Val Ser Pro Leu Pro Ser Ser Met Asp Leu Leu Ile Gln Asp
50
55
60
Ser Pro Asp Ser Ser Thr Ser Pro Lys Gly Lys Gln Pro Thr Ser Ala
65
70
75
80
Glu Asn Ser Val Ala Lys Lys Glu Asp Lys Val Pro Val Lys Lys Gln
85
90
95
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Lys Thr Arg Thr Val Phe Ser Ser Thr Gln Leu Cys Val Leu Asn Asp
100

105

110

Arg Phe Gln Arg Gln Lys Tyr Leu Ser Leu Gln Gln Met Gln Glu Leu
115

120

125

Ser Asn Ile Leu Asn Leu Ser Tyr Lys Gln Val Lys Thr Trp Phe Gln
130

135

140

Asn Gln Arg Met Lys Ser Lys Arg Trp Gln Lys Asn Asn Trp Pro Lys
145

150

155

160

Asn Ser Asn Gly Val Thr Gln Lys Ala Ser Ala Pro Thr Tyr Pro Ser
165

170

175

Leu Tyr Ser Ser Tyr His Gln Gly Cys Leu Val Asn Pro Thr Gly Asn
180

185

190

Leu Pro Met Trp Ser Asn Gln Thr Trp Asn Asn Ser Thr Trp Ser Asn
195

200

205

Gln Thr Gln Asn Ile Gln Ser Trp Ser Asn His Ser Trp Asn Thr Gln
210

215

220

Thr Trp Cys Thr Gln Ser Trp Asn Asn Gln Ala Trp Asn Ser Pro Phe
225

230

235

240

Tyr Asn Cys Gly Glu Glu Ser Leu Gln Ser Cys Met His Phe Gln Pro
245

250

255

Asn Ser Pro Ala Ser Asp Leu Glu Ala Ala Leu Glu Ala Ala Gly Glu
260

265

270

Gly Leu Asn Val Ile Gln Gln Thr Thr Arg Tyr Phe Ser Thr Pro Gln
275

280

285

Thr Met Asp Leu Phe Leu Asn Tyr Ser Met Asn Met Gln Pro Glu Asp
290

295

300

Val
305

What is claimed is:
1. A method of producing multiple stem cell populations
for storage in a stem cell bank comprising:
obtaining mesenchymal stem cells (MeSCs) from a subject;
dedifferentiating said MeSCs by introducing into said
MeSCs an expression cassette that expresses nanog
internally to thereby increase developmental potency of
said MeSCs;
expanding said MeSCs; and
cataloguing said MeSCs according to at least one predetermined characteristic;
wherein said at least one predetermined characteristic comprises morphological characteristics, differentiation profile,
blood type, major histocompatibility complex, disease state
of donor, or single nucleated polymorphisms a specific
nucleic acid sequence associated with a gene, or genomic or
mitochondrial DNA.
2. The method of claim 1, further comprising storing said
cell populations under conditions to keep said cell populations viable.
3. The method of claim 2, wherein said storing comprises
placing said cell populations in separate containers under
freezing conditions.
4. The method of claim 1, wherein said cataloguing comprises inputting information about said predetermined characteristic of a given cell population into a database computer.
5. The method of claim 4, wherein said predetermined
characteristic comprises disease state information of a donor.
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6. The method of claim 1, wherein said predetermined
characteristic comprises disease state information of donor.
7. A stem cell bank comprising:
stem cell populations produced by the method of claim 1
and possessed by a single provider, wherein said stem
cell populations comprise cells having an expression
cassette comprising a nanog gene; and
a catalogue comprising information of predetermined
characteristic information correlating with said stem cell
populations, wherein said predetermined characteristic
information comprises morphological characteristics,
differentiation profile, blood type, major histocompatibility complex, disease state of donor, or single nucleated polymorphisms a specific nucleic acid sequence
associated with a gene, or genomic or mitochondrial
DNA.
8. The stem cell bank of claim 7, wherein said catalogue is
at least one database computer unit comprising at least one
processing module and at least one memory device into which
predetermined characteristic information of said multiple cell
populations is inputted, and at least one program code module
that causes predetermined characteristic information to be
displayed onto a display which is in communication with said
database computer.
9. The stem cell bank of claim 7, further comprising at least
one freezer, wherein said cell populations are disposed within
said at least one freezer.
10. The stem cell bank of claim 9, wherein said at least one
freezer is in a building.

US 8,759,090 B2
16

15
11. The stem cell bank of claim 7, wherein said multiple

stem cell populations are individually placed within separate
containers.
12. A stem cell banking system for storage and making
available for purchase of stem cell populations comprising:
at least one freezer;
multiple stem cell populations produced by the method of
claim 1 placed within said at least one freezer to produce
stored stem cell populations, wherein said stem cell
populations comprise cells having an expression cassette comprising a nanog gene; and
at least one database computer unit comprising at least one
processing module and at least one memory device into
which predetermined characteristic information of said
multiple cell populations is inputted, and a computer
program product stored on said at least one memory
device, said computer program product comprising program code modules that causes said database computer
to:
receive a request for information from a user computer unit
onto a display which is in communication with said
database about said stored stem populations;
display information onto said display about stem cells in
response to said request;
display field to indicate intent to purchase at least one stem
cell sample; and
display confirmation of purchase of stem cells upon receiving a purchase indication.

* * * * *
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